The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / An Amylodosis Warning & New Drug Hope

An Amylodosis Warning & New Drug Hope

March 17, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Designua / shutterstock.com

Designua / shutterstock.com

SAN DIEGO—Treatments do exist that can improve the prospects of a patient with the rare disease amyloidosis, but only if clinicians keep the disease in mind and treat the patient before it’s too late, an expert said at the 2017 ACR/ARHP Annual Meeting this past November. He also discussed research that may be close to verifying a new drug treatment for the devastating disease.

You Might Also Like
  • 2015 ACR/ARHP Annual Meeting: Treatments for Transthyretin-Related Amyloidosis Generate Interest from Researchers, Pharmaceuticals
  • Amyloidosis Is Often Underdiagnosed, Undertreated
  • What Rheumatologists Need to Know about Identifying Amyloidosis
Explore This Issue
March 2018
Also By This Author
  • Researchers Work Toward Early ID & Treatment of Rheumatoid Arthritis

“The first and most important thing I want to say to you is, think amyloidosis,” said Sir Mark Pepys, MD, PhD, professor of medicine at University College London in England. Dr. Pepys has been studying amyloidosis for decades, and he founded the UK National Amyloidosis Center, also in London. “Please remember to think amyloidosis when you’re confronted with any clinical case at all. Systemic amyloidosis can mimic just about any clinical presentation you want to talk about, and if you don’t think of it, you’re not going to do the right diagnostic investigations. If you don’t make the diagnosis, the patient will suffer.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The disease is caused by an accumulation of abnormal protein fibers, called amyloid fibrils, that damage tissues and organs. The body can’t effectively clear these amyloid deposits, which are all but ignored by the normal mechanisms for debris removal. In systemic amyloidosis, the precursors of the fibrils are circulating globular proteins that become misfolded because of an instability that can be inherent, acquired or hereditary.

Rheumatologists are most likely to encounter amyloidosis that arises from chronic inflammatory conditions, but it has become less common as these diseases have been managed better. Amyloidosis is not the rarest disease, but “most clinicians have probably never seen a case, or know that they’ve seen a case, in their whole clinical career,” Dr. Pepys said. This means many patients aren’t diagnosed until they have advanced disease, and “as a result, their prognosis is dreadful despite major recent advances in treatment and much better outcomes [available] if you’re diagnosed and treated early in specialty centers.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Current & Future Treatments

The current idea behind disease treatment is to keep patients alive for as long as possible while efforts are made to remove the precursor protein forming the fibrils and improve the function of failing organs.

Genetic techniques (e.g., antisense oligonucleotides and a drug designed to silence specific messenger RNA) have been developed to target hereditary forms of amyloid deposition and have moved into Phase 3, with some encouraging results, Dr. Pepys said.

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports, Systemic Inflammatory Syndromes Tagged With: ACR/ARHP Annual Meeting, Amyloidosis, dezamizumab, miridesapIssue: March 2018

You Might Also Like:
  • 2015 ACR/ARHP Annual Meeting: Treatments for Transthyretin-Related Amyloidosis Generate Interest from Researchers, Pharmaceuticals
  • Amyloidosis Is Often Underdiagnosed, Undertreated
  • What Rheumatologists Need to Know about Identifying Amyloidosis
  • At Vasculitis Conference, Patients Share Hope, Humor & Hardships

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.